NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Brainstorm Cell Therapeutics Inc.

Shareholders who purchased shares of BCLI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/brainstorm-cell-loss-submission-form/?id=54999&from=3

CLASS PERIOD: August 15, 2022 to September 27, 2023

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Brainstorm Cell downplayed the severity of the refusal to file letter it received from the U.S. Food and Drug Administration ...

Full story available on Benzinga.com